MX2020004271A - Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo. - Google Patents
Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo.Info
- Publication number
- MX2020004271A MX2020004271A MX2020004271A MX2020004271A MX2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A
- Authority
- MX
- Mexico
- Prior art keywords
- dpp3
- binding
- conditions
- oxidative stress
- epitopes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17198420 | 2017-10-25 | ||
| PCT/EP2018/079197 WO2019081595A2 (en) | 2017-10-25 | 2018-10-24 | DPP3 BINDER DIRECTED TO AND BINDING SPECIFIC DPP3 EPITOPES AND USE THEREOF IN THE PREVENTION OR TREATMENT OF OXIDATIVE STRESS ASSOCIATED DISEASES / CONDITIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004271A true MX2020004271A (es) | 2020-07-29 |
Family
ID=60186108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004271A MX2020004271A (es) | 2017-10-25 | 2018-10-24 | Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11530276B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4527458A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7424972B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250111243A (cg-RX-API-DMAC7.html) |
| CN (2) | CN118791621A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018356441B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020006563A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3080251A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL274009B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020004271A (cg-RX-API-DMAC7.html) |
| MY (1) | MY202502A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202002594PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019081595A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11530276B2 (en) * | 2017-10-25 | 2022-12-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
| CN113557031A (zh) * | 2018-12-21 | 2021-10-26 | 4Teen4制药有限公司 | 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测 |
| EP4552649A3 (en) * | 2019-08-30 | 2025-06-25 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| AU2021228207A1 (en) * | 2020-02-27 | 2022-10-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock |
| EP4121763A1 (en) * | 2020-03-16 | 2023-01-25 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| CN120359042A (zh) | 2022-12-15 | 2025-07-22 | 4Teen4制药有限公司 | 改善危重病患者肺功能的dpp3抑制剂 |
| CN115804836A (zh) * | 2022-12-27 | 2023-03-17 | 中国人民解放军海军特色医学中心 | 一种中枢小分子蛋白dpp3在制备降压药物中的应用 |
| CN120857945A (zh) | 2023-03-29 | 2025-10-28 | 4Teen4制药有限公司 | 用于在血压下降的危重病患者中保护心肌和预防心肌损伤的dpp3抑制剂 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| JPS6188884A (ja) | 1984-10-04 | 1986-05-07 | Sankyo Co Ltd | エンケフアリナ−ゼｂ阻害物質およびその製法 |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2001016334A2 (en) | 1999-09-01 | 2001-03-08 | Incyte Genomics, Inc. | Human hydrolytic enzymes |
| WO2003020746A1 (en) | 2001-08-30 | 2003-03-13 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| WO2005106486A2 (en) | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3) |
| EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
| JP2006230318A (ja) | 2005-02-25 | 2006-09-07 | Maruishi Pharmaceutical Co Ltd | 関節リウマチの診断方法 |
| WO2007117444A2 (en) * | 2006-03-31 | 2007-10-18 | Yinghe Hu | Protein detection by aptamers |
| EP2302395B1 (en) | 2006-06-07 | 2015-04-15 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| EP2231860B1 (en) | 2007-12-19 | 2011-10-05 | Affibody AB | Polypeptide derived from protein a and able to bind pdgf |
| MX359570B (es) | 2008-11-03 | 2018-10-01 | Molecular Partners Ag | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
| US8715928B2 (en) | 2009-02-13 | 2014-05-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular-based method of cancer diagnosis and prognosis |
| EP2414542B1 (en) * | 2009-03-30 | 2017-08-30 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
| US9376477B2 (en) | 2009-08-27 | 2016-06-28 | Covagen Ag | IL-17 binding compounds and medical uses thereof |
| WO2011073214A2 (en) | 2009-12-14 | 2011-06-23 | Scil Proteins Gmbh | A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
| JP5902679B2 (ja) | 2010-06-08 | 2016-04-13 | ピエリス アーゲーＰｉｅｒｉｓ Ａｇ | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| CA2898596A1 (en) | 2013-01-28 | 2014-07-31 | Gabriel GOJON ROMANILLOS | Compositions for the systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| CN104946646B (zh) * | 2014-03-25 | 2020-03-31 | 中国医学科学院基础医学研究所 | 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用 |
| US20190145981A1 (en) * | 2016-04-21 | 2019-05-16 | Sphingotec Therapeutics Gmbh | Methods for determining dpp3 and therapeutic methods |
| US11530276B2 (en) * | 2017-10-25 | 2022-12-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
-
2018
- 2018-10-24 US US16/758,881 patent/US11530276B2/en active Active
- 2018-10-24 EP EP25153152.1A patent/EP4527458A3/en active Pending
- 2018-10-24 CA CA3080251A patent/CA3080251A1/en active Pending
- 2018-10-24 CN CN202410933184.0A patent/CN118791621A/zh active Pending
- 2018-10-24 KR KR1020257023507A patent/KR20250111243A/ko active Pending
- 2018-10-24 MY MYPI2020002078A patent/MY202502A/en unknown
- 2018-10-24 BR BR112020006563-3A patent/BR112020006563A2/pt unknown
- 2018-10-24 WO PCT/EP2018/079197 patent/WO2019081595A2/en not_active Ceased
- 2018-10-24 CN CN201880069013.0A patent/CN111542548B/zh active Active
- 2018-10-24 EP EP18795970.5A patent/EP3700937A2/en active Pending
- 2018-10-24 JP JP2020523261A patent/JP7424972B2/ja active Active
- 2018-10-24 SG SG11202002594PA patent/SG11202002594PA/en unknown
- 2018-10-24 MX MX2020004271A patent/MX2020004271A/es unknown
- 2018-10-24 AU AU2018356441A patent/AU2018356441B2/en active Active
- 2018-10-24 IL IL274009A patent/IL274009B2/en unknown
- 2018-10-24 KR KR1020207014841A patent/KR102835427B1/ko active Active
-
2022
- 2022-11-10 US US17/984,611 patent/US20230295344A1/en active Pending
-
2024
- 2024-01-18 JP JP2024006108A patent/JP2024041975A/ja active Pending
-
2025
- 2025-03-06 AU AU2025201656A patent/AU2025201656A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210206876A1 (en) | 2021-07-08 |
| CA3080251A1 (en) | 2019-05-02 |
| CN118791621A (zh) | 2024-10-18 |
| WO2019081595A2 (en) | 2019-05-02 |
| KR102835427B1 (ko) | 2025-07-21 |
| AU2025201656A1 (en) | 2025-03-27 |
| EP4527458A2 (en) | 2025-03-26 |
| US11530276B2 (en) | 2022-12-20 |
| JP2024041975A (ja) | 2024-03-27 |
| EP3700937A2 (en) | 2020-09-02 |
| IL274009A (en) | 2020-05-31 |
| MY202502A (en) | 2024-05-01 |
| IL274009B2 (en) | 2025-01-01 |
| BR112020006563A2 (pt) | 2020-10-13 |
| KR20200083509A (ko) | 2020-07-08 |
| JP7424972B2 (ja) | 2024-01-30 |
| AU2018356441A1 (en) | 2020-04-16 |
| US20230295344A1 (en) | 2023-09-21 |
| EP4527458A3 (en) | 2025-07-09 |
| WO2019081595A3 (en) | 2019-06-20 |
| SG11202002594PA (en) | 2020-04-29 |
| WO2019081595A4 (en) | 2019-09-06 |
| RU2020116450A3 (cg-RX-API-DMAC7.html) | 2021-12-21 |
| AU2018356441A9 (en) | 2024-12-19 |
| KR20250111243A (ko) | 2025-07-22 |
| CN111542548A (zh) | 2020-08-14 |
| RU2020116450A (ru) | 2021-11-25 |
| AU2018356441B2 (en) | 2024-12-19 |
| IL274009B1 (en) | 2024-09-01 |
| CN111542548B (zh) | 2024-07-30 |
| JP2021500376A (ja) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004271A (es) | Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo. | |
| AR106753A1 (es) | Proteínas de unión a ctla4p | |
| MX2022000112A (es) | Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3). | |
| ZA201801083B (en) | Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof | |
| CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| MX2019001503A (es) | Tratamiento conjunto contra el cancer. | |
| WO2019098763A3 (ko) | 알파-시누클레인에 대한 항체 및 그 용도 | |
| WO2013080147A3 (en) | Anticancer fusion protein | |
| MX359201B (es) | Polipeptidos que se unen al complemento humano 5 (c5). | |
| PL393578A1 (pl) | Przeciwnowotworowe białko fuzyjne | |
| CY1116646T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
| WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| MX390418B (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso. | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| PL394618A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| CO2019012204A2 (es) | Proteínas de unión al antígeno anti-jagged1 | |
| WO2016150415A8 (de) | Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz | |
| MX376994B (es) | Péptido c-terminal de acetilcolinesterasa cíclico para usarse en el tratamiento o la prevención de cáncer o metástasis. | |
| WO2020053742A3 (en) | Anti-hla-hbv peptide antibodies | |
| EA201692471A1 (ru) | Антиретровирусное лекарственное средство, нацеленное на эндогенный ретровирус человека | |
| PH12021552079A1 (en) | Albumin-bound composition including lrrd2 of slit3 protein for prevention or treatment of bone-related diseases | |
| CL2020000631A1 (es) | Uso de anticuerpos de unión a il-1b para el tratamiento de la hepatitis alcohólica. | |
| AR107012A1 (es) | ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A ErbB3 Y EL USO DEL MISMO |